Pregnancy After CAR-T in Autoimmune Disease: 14 Pregnancies, No Flares The first multicenter series of pregnancies after CAR T-cell therapy for autoimmune disease reports 8 healthy births and no maternal flares. It is the first dataset of its kind, and the numbers are small. https://t.co/uqWz8GeAmX

Menopause and Rheumatoid Arthritis: Are we asking enough? A study from Mayo Clinic at ACR Convergence, abstract 1849 examines menopause symptom burden in women with and without RA. Using two research datasets, Kristen Young and colleagues conducted a cross-sectional analysis of https://t.co/V3VJXo3z5w

Beyond HLA-B27: Anti-14-3-3eta Autoantibodies as a Candidate Marker in axSpA 14-3-3 proteins are a conserved family of seven isoforms with diverse cellular functions, found predominantly intracellularly. The 14-3-3eta isoform has been studied as a proinflammatory mediator in RA https://t.co/yC4bhtnTCD

PMR: Spare The Steroids Please Steroids remain both the cornerstone and the Achilles' heel of PMR management. We have aspirations of briskly tapering our patients once they have had their honeymoon phase with prednisone. But when Ms. Jones calls you with a reported second PMR https://t.co/dbrdVZRuoN

All RA-ILD deserves a trial of immunomodulation The optimum treatment approach in RA-ILD remains an area mired in controversy. This is evident from the contrasting views taken by the 2 recent expert guidelines from ACR and EULAR, which advocate for very different treatment https://t.co/vxr8NDruGI

IgG4-RD in 3 Talks: Shorter Steroids, Earlier B-Cell Therapy IgG4-related disease now has two phase 3 trials and its first dedicated treatment guidelines. Glucocorticoids remain the weak point. https://t.co/pWu1eoiMVG https://t.co/yXXk0R4Rbs

New Treatment for Fibromyalgia? Will It Help or Harm? For years, the pharmacologic treatment landscape for fibromyalgia has remained relatively unchanged, with limited therapeutic options despite a substantial disease burden. This condition is characterized by chronic https://t.co/nn9wu7xibY

Biologic Dosing and Obesity A 46-year-old with pSa and a BMI of 38 still has active disease on adalimumab (Humira) 40 mg every other week. What do you do? Stephen Balevic, MD, PhD, discusses this question in "Prescribing the Right Dose: How Obesity Alters Drug https://t.co/0SGQGs32U2

One Diagnosis, Different Diseases: Is TLR7/8 Inhibition the Future of Lupus Treatment? We call it systemic lupus erythematosus (SLE), but are we really treating one disease? Increasingly, I wonder whether grouping biologically distinct patients under one diagnosis is limiting https://t.co/30MGwIRUgO

Cardiovascular Risk in Rheumatoid Arthritis What is the link between cardiovascular risk and dementia? In abstract 1454, Michelle Allen and colleagues at Mayo Clinic studied 2,483 adults with incident RA diagnosed between 1980 and 2019. Patients were followed for Alzheimer’s https://t.co/JaITrlZXIt

ACR 2026 – Day 2 Report https://t.co/H5aJMSwHwk https://t.co/gzGSaA9czB

Are GLP-1s Doing More Than Shrinking Waistlines in PsA? In abstract #0373, Pankti Mehta and colleagues examined patients from a longitudinal PsA cohort who initiated GLP-1 receptor agonist or dual GIP/GLP-1 therapy and compared them with matched controls. Baseline body mass https://t.co/FGCszLnS4N

Scary IPAF IPAF describes patients who have ILD plus clinical, serologic, or morphologic features of autoimmunity but who do not meet criteria for a defined connective tissue disease. The 2015 ERS/ATS criteria proposed IPAF as a research classification, not a distinct disease, https://t.co/v3ir4IHia7

Beyond Joint Inflammation: Does Early RA Control Prevent Chronic Pain and Fatigue? Could the therapeutic window of opportunity in rheumatoid arthritis extend beyond preventing structural damage to preventing chronic pain, fatigue, and neuroimmune complications? This is the https://t.co/WVSjwIHOAM

Might stem cells actually work in knee OA?? Possibly, only the right combo 🇰🇷 OSCA: OS (allo mesenchymal stem cells) + CAM (cartilage acellular matrix) anti-inflamm, structural, pain ph2a impressive signal over placebo & maybe tissue repair, benefit out to 5y? #ACR26 @RheumNow https://t.co/PU3MUqxH7Q